Your browser doesn't support javascript.
loading
Outcomes of responders to PD-1/PD-L1 inhibitors who discontinue therapy after sustained disease control.
Sharma, Harsh; Moturi, Krishna R; Pankratz, Vernon S; Yilmaz, Emrullah; Gbolahan, Olumide B; Kumar, Atul; Hashemi-Sadraei, Neda.
Afiliação
  • Sharma H; Department of Internal Medicine, University of New Mexico, Albuquerque, NM, 87131, USA. hrsharma@salud.unm.edu.
  • Moturi KR; Department of Internal Medicine, University of New Mexico, Albuquerque, NM, 87131, USA.
  • Pankratz VS; University of New Mexico Comprehensive Cancer Center, Albuquerque, NM, 87102, USA.
  • Yilmaz E; Department of Internal Medicine, University of New Mexico, Albuquerque, NM, 87131, USA.
  • Gbolahan OB; University of New Mexico Comprehensive Cancer Center, Albuquerque, NM, 87102, USA.
  • Kumar A; Cleveland Clinic Taussig Cancer Center, Cleveland, OH, 44106, USA.
  • Hashemi-Sadraei N; Winship Cancer Institute at Emory University School of Medicine, Atlanta, GA, 30322, USA.
J Cancer Res Clin Oncol ; 149(11): 8673-8680, 2023 Sep.
Article em En | MEDLINE | ID: mdl-37115270
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Antineoplásicos Imunológicos / Neoplasias Renais Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Antineoplásicos Imunológicos / Neoplasias Renais Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article